Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Heparanase is preferentially expressed in human tumors and its over-expression in tumor cells. The enzyme also releases angiogenic factors from the ECM and thereby induces an angiogenic response. Heparanase exhibits also non-enzymatic activities, independent of its involvement in ECM degradation.

The Heparanase pipeline drugs market research report provides an analysis of the Heparanase drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Heparanase and features dormant and discontinued projects.

Key Therapy Areas of the Heparanase Pipeline Drugs Market

Some of the therapy areas of the Heparanase pipeline drugs market are Oncology, Infectious Disease, Ophthalmology, Hematological Disorders, and Immunology.

Heparanase Pipeline Drugs Market, by Therapy Areas

Heparanase Pipeline Drugs Market, by Therapy Areas

For more insights on key therapy areas, download a free report sample

Key Mechanisms of Action in the Heparanase Pipeline Drugs Market

The key mechanism of action of the Heparanase pipeline drugs market is Heparanase Inhibitor.

Key Routes of Administration in the Heparanase Pipeline Drugs Market

The routes of administration in the Heparanase pipeline drugs market are subcutaneous, intravenous, and oral.

Heparanase Pipeline Drugs Market, by Routes of Administration

Heparanase Pipeline Drugs Market, by Routes of Administration

For more insights on routes of administration, download a free report sample

Key Molecule Types in the Heparanase Pipeline Drugs Market

The molecule types in the Heparanase pipeline drugs market are Small Molecule, Polysaccharide, Peptide, and Synthetic Peptide.

Heparanase Pipeline Drugs Market, by Molecule Types

Heparanase Pipeline Drugs Market, by Molecule Types

For more insights on molecule type, download a free report sample

Key Companies in the Heparanase Pipeline Drugs Market

Some of the key companies in the Heparanase pipeline drugs market are B-Side Pharma Ltd, Beta Therapeutics Pty Ltd, CarboMimetics, HepaRx Ltd, Johnson & Johnson, Leadiant Biosciences Inc, Shenzhen Hepalink Pharmaceutical Group Co Ltd, and Zucero Therapeutics Ltd.

Heparanase Pipeline Drugs Market, by Companies

Heparanase Pipeline Drugs Market, by Companies

For more insights on companies, download a free report sample

Heparanase Pipeline Drugs Market Report Overview

Key Therapy Areas Oncology, Infectious Disease, Ophthalmology, Hematological Disorders, and Immunology
Key Mechanisms of Action Heparanase Inhibitor
Key Routes of Administration Subcutaneous, Intravenous, and Oral
Key Molecule Types Small Molecule, Polysaccharide, Peptide and Synthetic Peptide
Key Companies B-Side Pharma Ltd, Beta Therapeutics Pty Ltd, CarboMimetics, HepaRx Ltd, Johnson & Johnson, Leadiant Biosciences Inc, Shenzhen Hepalink Pharmaceutical Group Co Ltd and Zucero Therapeutics Ltd

Scope 

  • The report provides a snapshot of the global therapeutic landscape for Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166)
  • The report reviews Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

B-Side Pharma Ltd
Beta Therapeutics Pty Ltd
CarboMimetics
HepaRx Ltd
Johnson & Johnson
Leadiant Biosciences Inc
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Zucero Therapeutics Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) – Overview

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) – Companies Involved in Therapeutics Development

B-Side Pharma Ltd

Beta Therapeutics Pty Ltd

CarboMimetics

HepaRx Ltd

Johnson & Johnson

Leadiant Biosciences Inc

Shenzhen Hepalink Pharmaceutical Group Co Ltd

Zucero Therapeutics Ltd

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) – Drug Profiles

BT-2180 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CM-30119 – Drug Profile

Product Description

Mechanism Of Action

H-1710 – Drug Profile

Product Description

Mechanism Of Action

History of Events

JVB-001 – Drug Profile

Product Description

Mechanism Of Action

JVB-002 – Drug Profile

Product Description

Mechanism Of Action

JVB-003 – Drug Profile

Product Description

Mechanism Of Action

JVB-14 – Drug Profile

Product Description

Mechanism Of Action

History of Events

necuparanib – Drug Profile

Product Description

Mechanism Of Action

History of Events

pixatimod – Drug Profile

Product Description

Mechanism Of Action

History of Events

Polysaccharides to Inhibit Heparanase for Unspecified Cancer – Drug Profile

Product Description

Mechanism Of Action

roneparstat – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit Heparanase for Oncology – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit Heparanase for Inflammatory Diseases and Oncology – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit Heparanase for Type 1 and Type 2 Diabetes and Age Related Macular Degeneration – Drug Profile

Product Description

Mechanism Of Action

History of Events

Synthetic Peptide to Inhibit HPSE and VEGF for Oncology – Drug Profile

Product Description

Mechanism Of Action

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) – Dormant Products

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) – Discontinued Products

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC

3.2.1.166) – Product Development Milestones

Featured News & Press Releases

Aug 04, 2016: Momenta Discontinues Further Accrual of its Phase 2 Trial of Necuparanib in Patients with Pancreatic Cancer Following Planned Interim Futility Analysis

Jun 04, 2016: Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO

May 19, 2016: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting

Dec 21, 2015: Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study

Nov 13, 2015: Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study

Jun 01, 2015: Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer

May 18, 2015: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib (M402) at the 2015 ASCO Annual Meeting

Dec 01, 2014: Momenta Pharmaceuticals’ Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer

Oct 09, 2014: Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer

Oct 09, 2014: Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer

Jul 21, 2014: European Patent Office Intention to Grant ‘Sulfated Oligosaccharide Derivatives’ Patent

Jun 05, 2014: Momenta Pharmaceuticals Receives Orphan Drug Designation for Necuparanib (Formerly M402) in Pancreatic Cancer

Oct 29, 2013: PG545 Phase 1 Cancer Trial Update

Jul 09, 2013: PG545 Pre-Clinical Data in Experimental Pancreatic Cancer Models Published in Molecular Cancer Therapeutics

May 13, 2013: Sigma-Tau announces Phase I study with new anti-cancer heparanase inhibitor SST0001

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by B-Side Pharma Ltd, 2022

Pipeline by Beta Therapeutics Pty Ltd, 2022

Pipeline by CarboMimetics, 2022

Pipeline by HepaRx Ltd, 2022

Pipeline by Johnson & Johnson, 2022

Pipeline by Leadiant Biosciences Inc, 2022

Pipeline by Shenzhen Hepalink Pharmaceutical Group Co Ltd, 2022

Pipeline by Zucero Therapeutics Ltd, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.